Janus Henderson Group plc reported beneficial ownership of 798,382 shares of Common Stock of Cellectar Biosciences, Inc. The filing states this equals 9.99% of the class and discloses additional holdings of 1,051,520 pre-funded warrants and 1,886,792 Series A, B, and C warrants each, with exercise limitations described in the filing. The disclosure is filed on behalf of Janus Henderson and affiliated asset managers and is signed on 06/05/2026.
Positive
None.
Negative
None.
Insights
Janus Henderson disclosed a near-10% passive position in CLRB with significant warrant holdings.
The schedule shows Janus Henderson Group plc and affiliated asset managers beneficially own 798,382 shares of Common Stock, representing 9.99% of the class. The filing also lists 1,051,520 pre-funded warrants and 1,886,792 Series A, B, and C warrants each, subject to a 9.99% ownership cap.
Cash-flow treatment and intent to dispose are not described in the excerpt; subsequent filings or transaction reports would show any sales or exercises and their timing.
Key Figures
Common shares beneficially owned:798,382 sharesPercent of class:9.99%Pre-funded warrants:1,051,520 warrants+4 more
7 metrics
Common shares beneficially owned798,382 sharesSchedule 13G reporting beneficial ownership
Percent of class9.99%Percent of common stock beneficially owned
Pre-funded warrants1,051,520 warrantsPre-funded warrants disclosed in Item 4
Series A warrants1,886,792 warrantsSeries A warrants disclosed in Item 4
Series B warrants1,886,792 warrantsSeries B warrants disclosed in Item 4
Series C warrants1,886,792 warrantsSeries C warrants disclosed in Item 4
Filing signature date06/05/2026Signature block date for the Schedule 13G
"the Asset Managers may be deemed to be the beneficial owner of 1,051,520 pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Schedule 13Gregulatory
"Item 1. (a) Name of issuer: CELLECTAR BIOSCIENCES, INC."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Managed Portfoliosfinancial
"the Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include... Managed Portfolios"
beneficial ownershipregulatory
"Amount beneficially owned: Janus Henderson Group plc ... may be deemed to be the beneficial owner of 798,382 common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CELLECTAR BIOSCIENCES, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
15117F880
(CUSIP Number)
05/29/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
15117F880
1
Names of Reporting Persons
JANUS HENDERSON GROUP PLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
798,382.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
798,382.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
798,382.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CELLECTAR BIOSCIENCES, INC.
(b)
Address of issuer's principal executive offices:
100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
Item 2.
(a)
Name of person filing:
Janus Henderson Group plc
(b)
Address or principal business office or, if none, residence:
201 Bishopsgate
EC2M 3AE, United Kingdom
(c)
Citizenship:
Y9
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
15117F880
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Janus Henderson Group plc (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, and Victory Park Capital Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 798,382 common stock, as well as an additional 1,051,520 pre-funded warrants, 1,886,792 Series A Warrants, 1,886,792 Series B Warrants, and 1,886,792 Series C Warrants, which cannot be exercised to the extent they result in ownership in excess of 9.99% of Cellectar Biosciences, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)
Percent of class:
9.99 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
798382
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
798382
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.
Of the Managed Portfolios, only the Janus Henderson Biotech Innovation Master Fund Ltd. has the right to receive dividends from, or the proceeds from the sale of, more than five percent of the common stock of Cellectar Biosciences, Inc. Due to an irrevocable delegation of investment and voting discretion to an Asset Manager on less than 60 days notice, the Fund is not considered a Reporting Person under Section 13(d) and (g).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please refer to Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Janus Henderson hold in Cellectar Biosciences (CLRB)?
Janus Henderson beneficially owns 798,382 shares, equal to 9.99% of the common stock. The filing lists this percent and the share count as the disclosed beneficial position.
Does the filing disclose other instruments besides common stock?
Yes. The filing discloses 1,051,520 pre-funded warrants and 1,886,792 Series A, Series B, and Series C warrants each. The filing states exercise is limited to avoid exceeding 9.99% ownership.
Who is listed as the reporting person for the 13G?
The reporting person is Janus Henderson Group plc, filing on behalf of affiliated asset managers that exercise investment and voting discretion for managed portfolios.
Does the Schedule 13G state whether Janus Henderson will sell shares?
The excerpt does not describe any proposed sales or proceeds treatment. It explains the asset managers exercise discretion for managed portfolios but does not state intent to buy or sell.
When was the Schedule 13G signed for this disclosure?
The signature block shows the filing was signed by Kristin Mariani, Head of North America Compliance, on 06/05/2026.
